Ali Murat Tatli
Overview
Explore the profile of Ali Murat Tatli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
157
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bayramgil A, Bilici A, Tatli A, Kahraman S, Altintas Y, Akgul F, et al.
Medicina (Kaunas)
. 2025 Feb;
61(2).
PMID: 40005456
: The study aimed to compare the treatment effectiveness of patients with locally advanced rectal cancer undergoing standard neoadjuvant therapy or total neoadjuvant therapy. It also sought to identify prognostic...
2.
Bozcuk H, Sert L, Kaplan M, Tatli A, Karaca M, Muglu H, et al.
Cancers (Basel)
. 2025 Jan;
17(2).
PMID: 39858018
Background: Although higher-generation TKIs are associated with improved progression-free survival in advanced NSCLC patients with EGFR mutations, the optimal selection of TKI treatment remains uncertain. To address this gap, we...
3.
Ozbay M, Harputluoglu H, Karaca M, Tekin O, Sendur M, Kaplan M, et al.
Cancers (Basel)
. 2024 Nov;
16(22).
PMID: 39594835
Background And Aims: During liver transplantation, hepatocellular carcinoma (HCC) recurrence remains a critical challenge for patient survival. Targeted therapies, such as sorafenib and regorafenib, have been utilized to manage relapsed...
4.
Caglayan D, Kocak M, Geredeli C, Atci M, Tatli A, Sezgin Goksu S, et al.
Future Oncol
. 2024 Sep;
20(38):3099-3105.
PMID: 39316555
Endocrine therapy (ET) plus cyclin-dependent kinase (CDK) 4/6 inhibitors is a standard treatment for hormone receptor (HR) positive HER-2-negative metastatic breast cancer patients. In this study, we aimed to investigate...
5.
Kilickap S, Ozturk A, Karadurmus N, Korkmaz T, Yumuk P, Cicin I, et al.
Medicine (Baltimore)
. 2024 May;
103(21):e37972.
PMID: 38787994
To evaluate radiological and clinical features in metastatic anaplastic lymphoma kinase+ non-small cell lung cancer patients and crizotinib efficacy in different lines. This national, non-interventional, multicenter, retrospective archive screening study...
6.
Yavuz A, Simsek K, Alpsoy A, Altunay B, Gedik E, Unal B, et al.
World J Gastrointest Pathophysiol
. 2024 Apr;
15(1):91237.
PMID: 38682027
Background: Recent studies have shown that the tumor microenvironment significantly influences the behavior of solid tumors. In this context, Accumulated data suggests that pathological evaluation of tumor budding (TB), desmoplastic...
7.
Kahraman S, Karakaya S, Kaplan M, Sezgin Goksu S, Ozturk A, Isleyen Z, et al.
Sci Rep
. 2024 Mar;
14(1):5820.
PMID: 38461209
Central nervous system (CNS) metastases can be seen at a rate of 30% in advanced stages for patients with non-small cell lung cancer (NSCLC). Growing evidence indicates the predictive roles...
8.
Unal C, Azizy A, Karabulut S, Tastekin D, Akyildiz A, Yasar S, et al.
Oncologist
. 2023 Sep;
28(10):875-884.
PMID: 37676712
Introduction: This study aims to report the efficacy and safety of capecitabine plus temozolomide (CAPTEM) across different lines of treatment in patients with metastatic neuroendocrine tumors (NETs). Methods: We conducted...
9.
Guner G, Aktas B, Bugdayci Basal F, Demirkazik A, Gursoy P, Demirci U, et al.
J Cancer Res Clin Oncol
. 2023 Jul;
149(14):13271-13277.
PMID: 37480524
Purpose: Anaplastic lymphoma kinase (ALK) mutations occurs in approximately 3-5% of patients with non-small cell lung cancer (NSCLC). Pleural involvement/effusion is common in ALK-positive patients with NSCLC at baseline. The...
10.
Bardakci M, Esmer D, Hafizoglu E, Yaslikaya S, Genc T, Ozcelik M, et al.
Oncology
. 2023 Jun;
101(11):723-729.
PMID: 37379817
Introduction: In the adjuvant treatment of low-risk stage III colon cancer treated surgically, 3 months of CAPOX followed by 3 months of capecitabine is not a common clinical practice. Since...